INFUSION DRUG DELIVERY ARTICLES

fundamental comparison metaphor or analogy-GettyImages-2191773530 Comparing Advanced Modality Needs, Part 1: Manufacturing

ADCs, AOCs, ATMPs, cell and gene therapies, and oligonucleotide therapeutics represent distinct but interconnected approaches to precision medicine. Let's take a closer look at their manufacturing needs.

INFUSION DRUG DELIVERY VIDEOS

In this Live event segment, panelists Paul Upham and Monica Swinney discuss the cost benefits of gathering real world evidence from digital monitoring tools to support patient adherence and improved health outcomes.

What is management’s responsibility in the implementation of approaches to the new QMSR? In this segment of the Drug Delivery Leader Live event New FDA QMSR: Its Role in Part 4 Compliance for Combination Products, consultant Laurie Auerbach of Compliance Prodigies underscores the criticality of management commitment to and engagement in the process.

In this segment of the Drug Delivery Leader Live online event, Large Molecule Biologics Delivery: Aligning Formulations, Doses, And Devices, Chief Editor Tom von Gunden directs an audience question about the linkage between the QTPP (Quality Target Product Profile) and the Control Strategy to panelist Rubi Burlage. She identifies three fundamental aspects of the quality and control relationship: raw materials, process controls, and batch consistency. 

A common challenge in administering cell therapies and other biologics-based treatments is sustaining delivery and bioavailability while protecting against degradation and off-target toxicities. In this episode of Supplier Horizons, host Tom von Gunden discusses with CEO Stella Vnook from platform technology developer Likarda methods for deploying hydrogel microencapsulation to safely route cells, proteins, and other biologic agents to therapeutic targets. These include long-acting formulations in oncology, immunology, and other chronic or rare diseases. 

INFUSION DRUG DELIVERY RESOURCES

INFUSION DRUG DELIVERY SOLUTIONS

  • By partnering with Battelle, your organization can reduce risks and save on investment costs, leading to more successful and sustainable outcomes.

  • Capabilities that improve efficiency and accelerate development.

    B. Braun's OEM Division offers a variety of in-house molding capabilities including injection molding, insert molding and over molding. They own a primary 400,000-square-foot U.S. plant that includes a 16,500-square-foot ISO Class 8 molding facility housing some of B. Braun’s 80 injection molding presses, which range from 55-330 tons.

  • These containers can be delivered with a full line of solutions used in clinical settings, including basic saline, heparin premix, and lidocaine. The chemistry used to produce the container uses neither polyvinyl chloride (PVC) nor the plasticizer DEHP.

  • Learn how our team of scientists, engineers, and human-centered designers, as well as our world-class facilities, empower us to confidently guide your product toward a successful market launch.

  • Examine a NVGD platform that tackles the primary obstacle hindering gene editing therapies: efficient delivery. Utilizing engineered nanoparticles, the platform overcomes limitations associated with payload size.

  • This comprehensive suite of services encompasses the entire spectrum of user research, starting from the conceptualization of study designs to meticulous data analysis and comprehensive reporting.

  • RASR filling and closing machines are designed to treat IV bags. These machines are able to fill single chamber as well as dialysis multi-chambers bags.

  • BD Neopak™ XtraFlow™ Glass Prefillable Syringe solution leverages 8 mm needle length in combination with thin wall cannula to reduce pressure drop and enhance flow.

  • In recent years, hospitals, clinics, and others have experienced chronic shortages of medical solutions. The Solutions for Life initiative is a billion-dollar investment in meeting nationwide demand for these products.